ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 118 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q3 2022. The put-call ratio across all filers is 0.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $649,226 | -72.1% | 25,410 | -68.7% | 0.00% | -100.0% |
| Q2 2023 | $2,325,088 | +325.4% | 81,070 | +255.6% | 0.00% | – |
| Q1 2023 | $546,516 | +41.3% | 22,800 | 0.0% | 0.00% | – |
| Q4 2022 | $386,688 | +14.4% | 22,800 | 0.0% | 0.00% | – |
| Q3 2022 | $338,000 | -17.8% | 22,800 | -12.6% | 0.00% | – |
| Q2 2022 | $411,000 | -41.6% | 26,100 | 0.0% | 0.00% | – |
| Q1 2022 | $704,000 | -27.1% | 26,100 | 0.0% | 0.00% | – |
| Q4 2021 | $966,000 | -22.5% | 26,100 | 0.0% | 0.00% | – |
| Q3 2021 | $1,247,000 | +22.4% | 26,100 | -13.3% | 0.00% | – |
| Q2 2021 | $1,019,000 | -18.0% | 30,100 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $1,243,000 | -4.8% | 30,100 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,306,000 | +89.0% | 30,100 | +87.0% | 0.00% | – |
| Q3 2020 | $691,000 | -11.5% | 16,100 | -3.6% | 0.00% | – |
| Q2 2020 | $781,000 | – | 16,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 456,390 | $5,541,000 | 3.62% |
| DAFNA Capital Management LLC | 173,914 | $1,890,000 | 0.65% |
| One68 Global Capital, LLC | 19,861 | $216,000 | 0.47% |
| Diametric Capital, LP | 51,982 | $565,000 | 0.41% |
| ARK Investment Management | 1,383,756 | $15,041,000 | 0.38% |
| EAM Investors, LLC | 52,833 | $574,000 | 0.13% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 31,404 | $341,000 | 0.05% |
| Nikko Asset Management Americas, Inc. | 280,548 | $3,050,000 | 0.05% |
| MGO ONE SEVEN LLC | 14,900 | $161,000 | 0.04% |
| Qube Research & Technologies Ltd | 67,702 | $736,000 | 0.02% |